The Texas Medical Center Regional Coordinating Center for Heart Failure

描述(由申请人提供)： 得克萨斯医疗中心心力衰竭区域协调中心 拟建的德克萨斯医疗中心(TMC)区域协调中心(RCC)将由9个独立的地点组成，分别位于德克萨斯医疗中心(www.tmc.edu)的园区内，该中心是世界上最大的合并医疗中心之一，拥有42家非营利性机构，包括13家医院、两所医学院、两所生物医学研究生院、一所牙科学校、四所护理学校、一所公共卫生学校、一所药房、一所临终关怀机构、一个老年病中心、一个精神病学中心和一个法医医学中心，所有这些机构都位于同一校园内。TMC每年的就诊量超过500万人次，这使TMC成为进行临床试验的理想地点。此外，TMC内的种族和民族多样性非常适合进行临床试验。拟议中的RCC的科学和管理基地将设在贝勒医学院。TMC RCC中的九个站点彼此非常接近(见图1)，并且大多数由天桥和隧道连接，以促进站点之间的交互和协作。每个参与机构的患者特征、心力衰竭临床研究经验和心力衰竭临床试验的招募能力都很突出。最后，拟议的TMC RCC具有许多非常适合NIH心力衰竭研究网络的独特功能，包括所有参与机构离彼此很近，因此一名研究协调员可以从TMC网络的所有地点进行招聘，患者群体具有足够的种族多样性，以确保充分招募少数族裔和女性，社区和教学医院、儿科和成人医院以及专科医院(如MD Anderson)都有很高的成人和儿科心力衰竭患者数量。最后，TMC RCC将由Douglas Mann博士监督，他在I-IV期临床试验方面有经验，由于他在德克萨斯医学中心工作了14年，与拟议的TMC RCC的研究人员之一有着密切的工作关系。(摘要结束)

DESCRIPTION (provided by applicant): The Texas Medical Center Regional Coordinating Center for Heart Failure The proposed Texas Medical Center (TMC) Regional Coordinating Center (RCC) will be comprised of nine separate sites that are housed on the campus of the Texas Medical Center (www.tmc.edu), one of the largest incorporated medical centers in the world, with 42 not-for-profit institutions including 13 hospitals, two medical schools, two graduate schools of biomedical sciences, a dental school, four nursing schools, a school of public health, a college of pharmacy, a hospice facility, a geriatric center, a psychiatric center, and a forensic medical center, all located on the same campus. There are over 5,000,000 patient visits to the TMC, annually, which makes the TMC an ideal site to conduct clinical trials. Moreover, the racial and ethnic diversity within the TMC lends itself well to conducting clinical trials. The scientific and administrative base of this proposed RCC will be at Baylor College of Medicine. The nine sites in the TMC RCC are in close proximity to one another (see Figure 1), and most are attached by skywalks and tunnels that facilitate the interaction and collaboration between the sites. The patient characteristics, experience in clinical research in heart failure and enrollment capacity for heart failure clinical trials at each of the participating institutions is outstanding. Finally, the proposed TMC RCC has a number of unique features that are ideally suited for the NIH heart failure research network, including close proximity of all participating Institutions to one another such that a single research coordinator can recruit from all sites in the TMC network, sufficient racial diversity of the patient population to ensure adequate recruitment of minorities and women, a mixture of community and teaching hospitals, pediatric and adult hospitals, and specialty hospitals (e.g. MD Anderson), each of which has a very high patient volume for adult and pediatric heart failure. Finally the TMC RCC will be overseen by Dr. Douglas Mann, who has experience with phase I - IV clinical trials, and who has close working relationship with of the investigators in the proposed TMC RCC by virtue of his 14 year tenure in the Texas Medical Center. (End of Abstract)